Early Tuesday morning, Rigel Pharmaceuticals (NASDAQ: RIGL) and its now-ex-partner, AstraZeneca (NYSE: AZN), reported late-stage clinical trial results for the experimental rheumatoid arthritis drug Fostamatinib. In the following video, health-care analyst Max Macaluso discusses why Rigel dropped 18% after the news was released and the risks that lie ahead for Rigel Pharmaceuticals.
More from The Motley Fool
6 Ways to Make Your Retirement Savings Last
Breaking a big retirement rule is one of them.
Can You Really Make Money Mining Bitcoins?
Profits are not easy to come by. Expensive hardware and risky cloud mining deals are the main challenges.
3 Things to Watch in the Stock Market This Week
Look for Netflix, P&G, and Starbucks to make big moves over the next few trading days.